“Accelerating drug discovery by capturing the 'now' of living cells”

Our Opto-diagnostics (FRET biosensors) offer an unprecedented approach to drug discovery support by visualizing disease-relevant molecular dynamics in living cells at single-cell resolution.
In real time, we capture the molecular responses that distinguish drug-sensitive cells from drug-resistant ones.

･Enhancing the precision of target selection
･Enhancing the success rate of clinical trials
･Helping to reduce the reliance on animal testing

Advancing precision medicine by delivering precisely effective therapies faster.

Advancing precision medicine by delivering precisely effective therapies faster.

scroll

Expandability of the Opto-Diagnostic Reagent Palette

Our Opto-diagnostics are designed with a modular (cassette-like) architecture, allowing flexible adaptation to a wide range of disease-relevant proteins and signaling molecules.
This expandability supports the development of a diverse lineup of Opto-diagnostics?one of the key strengths of our platform.

Pipelines

CML: chronic myeloid leukemia; EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma; CRC: colorectal carcinoma; RA: rheumatoid arthritis

*Custom designs available upon request.

A Versatile Platform for Drug Discovery and Beyond

Our Opto-diagnostics address critical needs in drug discovery, including efficient target identification and cost reduction. By enabling single-cell analysis in living cells, we provide a powerful foundation for high-resolution, biology-driven decision-making.
Our platform supports a broad range of applications across the drug development pipeline, including:

Drug Discovery Platform - Example (1):
Characterization of Drug-Resistant Cells in Patient Samples

Following the identification of drug-resistant cells using our Opto-diagnostics, these cells can be isolated by fluorescence-activated cell sorting (FACS) and subjected to in-depth analyses, including single-cell RNA sequencing.
This approach enables the efficient discovery of novel therapeutic targets.

Case Study (1):
Identification and Isolation of Drug-Resistant Cells Using Opto-Diagnostics and FACS

Case Study (1), continued:
Microarray and Pathway Analysis (FRET-high vs FRET-low)

We welcome collaborative research and contract-based analysis.
Please feel free to contact us at the email address below for inquiries:

CONTACT